GOING试验:瑞戈非尼二线早期联合纳武利尤单抗治疗肝细胞癌
GOING是一项研究者发起的I/IIa期试验,评估瑞戈非尼联合纳武利尤单抗(add-on)用于索拉非尼进展(队列A)或阿替利珠单抗-贝伐珠单抗停药(队列B)的肝细胞癌患者。共纳入67例(75.5% BCLC-C),主要终点安全性:所有患者发生不良事件,9%导致停药,严重治疗相关不良事件总体28.4%。中位总生存期20.0个月(95%CI 11-37),36个月生存率40.6%;队列A中位OS 25个月(95%CI 14-39),36个月生存率45%。
要点
- 瑞戈非尼二线早期联合纳武利尤单抗安全性可控,严重治疗相关不良事件28.4%。
- 总体中位OS达20.0个月,36个月生存率40.6%。
- 索拉非尼进展者(队列A)中位OS 25个月,36个月生存率45%。
核心结论
- 瑞戈非尼联合纳武利尤单抗二线add-on策略安全性可控,中位OS达20个月,索拉非尼进展者3年生存率45%。
研究设计与样本
- GOING研究者发起的I/IIa期试验,纳入索拉非尼进展(队列A)或阿替利珠单抗-贝伐珠单抗停药(队列B)的肝细胞癌患者。
- 患者先接受瑞戈非尼两个28天周期,第3周期加入纳武利尤单抗,直至不可接受不良事件、症状性进展、退出或死亡。
- 共筛查85例,纳入67例(75.5% BCLC-C);主要终点为安全性。
主要发现
- 所有患者发生不良事件,9%导致停药;严重治疗相关不良事件总体28.4%,队列A 32.1%,队列B 14.3%。
- 中位总生存期20.0个月(95%CI 11-37),36个月生存率40.6%。
- 队列A中位OS 25个月(95%CI 14-39),36个月生存率45%;队列B中位OS 8个月(95%CI 4-NE),24个月生存率28.6%。
- 客观缓解率16.4%;中位至进展时间5个月(95%CI 4-9),进展后生存期14个月(95%CI 8-33)。
- 肝内进展为最常见进展模式,其次为新发肝外转移。
临床怎么用
- 对于索拉非尼进展的肝细胞癌患者,可考虑瑞戈非尼早期联合纳武利尤单抗,但需密切监测不良事件。
- 免疫治疗进展后,机制导向的临床试验值得进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Highly effective second-line treatments for hepatocellular carcinoma remain an unmet need. The GOING investigator-initiated Phase I/IIa trial evaluated regorafenib plus nivolumab (add-on) in patients who progressed on sorafenib (Cohort-A) or discontinued atezolizumab-bevacizumab (Cohort-B). METHODS: Patients received regorafenib for two 28-day cycles, adding nivolumab in cycle 3, until unacceptable adverse events, symptomatic progression, withdrawal or death. Primary endpoint was safety. Secondary endpoints included overall survival, time to progression, post-progression survival, objective response rate and incidence of new-extrahepatic-spread. RESULTS: Of 85 patients screened, 67 were enrolled (75.5% BCLC-C). All experienced adverse events and 9% led to discontinuation. Severe treatment-related adverse events occurred in 28.4% overall, 32.1% in Cohort-A, and 14.3% in Cohort-B. Median overall survival was 20.0 (95% CI 11-37) months, with 40.6% survival at 36 months. In Cohort-A, median overall survival was 25 (95% CI 14-39) months with 45% survival at 36 months, while Cohort-B median overall survival was 8 (95% CI 4-NE) months with 28.6% survival at 24 months. Objective response rate was 16.4%; median time to progression and post-progression survival were 5 (95% CI 4-9) months and 14 (95% CI 8-33) months. Intrahepatic growth was the most common progression pattern, followed by new-extrahepatic-spread. CONCLUSIONS: The add-on strategy of regorafenib plus nivolumab in second-line had manageable safety and significant clinical activity with a noteworthy median overall survival of 20 months. Among those progressing on sorafenib, 45% were alive at 3 years. These findings support further evaluation with mechanism-guided trials after progression on immunotherapy. TRIAL REGISTRATION: EudraCT number: 2019-003108-10; https://www.clinicaltrialsregister.eu.
引用
- Sanduzzi-Zamparelli M, Matilla A, Lledo JL, et al. Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial). Aliment Pharmacol Ther. 2026. PMID: 41725391. doi:10.1111/apt.70578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。